Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 (S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD).

× No keyword cloud information.

3 in total

1. The economic burden of depression in the United States: how did it change between 1990 and 2000?

Authors: Paul E Greenberg; Ronald C Kessler; Howard G Birnbaum; Stephanie A Leong; Sarah W Lowe; Patricia A Berglund; Patricia K Corey-Lisle
Journal: J Clin Psychiatry Date: 2003-12 Impact factor: 4.384

2. The top prescription drugs of 2009 in the US: CNS therapeutics rank among highest grossing.

Authors: Craig W Lindsley
Journal: ACS Chem Neurosci Date: 2010-06-16 Impact factor: 4.418

Review 3. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity.

Authors: Patrick M Lippiello; Jessica S Beaver; Gregory J Gatto; John W James; Kristen G Jordan; Vincent M Traina; Jianxun Xie; Merouane Bencherif
Journal: CNS Neurosci Ther Date: 2008 Impact factor: 5.243

3 in total

6 in total

Review 1. Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.

Authors: Paul R Sanberg; Cecilia Vindrola-Padros; R Douglas Shytle
Journal: Physiol Behav Date: 2012-07-06

6. Molecular interactions between mecamylamine enantiomers and the transmembrane domain of the human α4β2 nicotinic receptor.

Authors: Vasyl Bondarenko; Katarzyna M Targowska-Duda; Krzysztof Jozwiak; Pei Tang; Hugo R Arias
Journal: Biochemistry Date: 2014-01-30 Impact factor: 3.162

6 in total

(S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD).

1. The economic burden of depression in the United States: how did it change between 1990 and 2000?

2. The top prescription drugs of 2009 in the US: CNS therapeutics rank among highest grossing.

Review 3. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity.

Review 1. Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.

Review 2. Functional brain imaging of nicotinic effects on higher cognitive processes.

Review 3. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.

Review 4. Citalopram versus other anti-depressive agents for depression.

5. Similar activity of mecamylamine stereoisomers in vitro and in vivo.

6. Molecular interactions between mecamylamine enantiomers and the transmembrane domain of the human α4β2 nicotinic receptor.